DPP-4 inhibitors may up risk of bullous pemphigoid
Use of dipeptidyl-peptidase 4 (DPP-4) inhibitors is linked to the development of bullous pemphigoid, although the risk increase appears to be limited to linagliptin, according to the results of a meta-analysis.
